Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present MediGene AG (OTC: MDGEF).

Full DD Report for MDGEF

You must become a subscriber to view this report.


Recent News from (OTC: MDGEF)

Road To Financial Independence: Growing Dividends, Endless Opportunities But Limited Capital
The stock markets never stop to amaze me. While July was heavily driven by concerns about a deteriorating trade war, August, in general, was a big rally, with markets hitting new highs and the euro dropping down to as low as $1.13. Overall net capital spending was around $2,650 as I divested...
Source: SeekingAlpha
Date: September, 03 2018 02:53
MediGene AG 2018 Q2 - Results - Earnings Call Slides
The following slide deck was published by MediGene AG in conjunction with their 2018 Q2 earnings Read more ...
Source: SeekingAlpha
Date: August, 08 2018 13:58
MediGene AG reports 1H results
MediGene AG ( OTCPK:MDGEF ): 1H Net loss of €7.2M Revenue of €5.5M (+12.2% Y/Y) Press Release More news on: MediGene AG, Earnings news and commentary, Tech stocks news, ,
Source: SeekingAlpha
Date: August, 07 2018 18:03
Road To Financial Independence: My March 89-Stock Portfolio Review
As markets have been waiting for the earnings season to kick in, they got shaken day after day by some wild volatility-driven swings, which in turn were mostly fueled by trade war concerns and a very hawkish Federal Reserve. On top of that, some core holdings such as Altria (MO) and AbbVie (...
Source: SeekingAlpha
Date: April, 11 2018 08:30
MediGene AG 2017 Q4 - Results - Earnings Call Slides
The following slide deck was published by MediGene AG in conjunction with their 2017 Q4 earnings Read more ...
Source: SeekingAlpha
Date: March, 26 2018 14:33
Road To Financial Independence: My February 88-Stock Portfolio Review With Big Apple Purchase
February was a terrific month, with the U.S. stock market briefly plummeting more than 10% (officially in correction mode) in one of the worst weeks since the financial crisis. This triggered some heavy buying on my side, as I was trying to blend out all the noise and anxiety about rising Tr...
Source: SeekingAlpha
Date: March, 13 2018 09:15
3 Things In Biotech You Should Learn Today: February 23, 2018
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotec...
Source: SeekingAlpha
Date: February, 24 2018 08:00
Road To Financial Independence: My December 88-Stock Portfolio Review
First of all, Happy New Year everybody! 2017 has been a special year with global stock markets, particularly the US markets, rallying strongly. The broad S&P 500 (NYSEARCA: SPY ) almost gained 20% and was outperformed significantly by the Dow Jones (+25%) and the tech-heavy Nasdaq (+32...
Source: SeekingAlpha
Date: January, 15 2018 08:42
My Journey To Financial Independence: 86-Stock November Portfolio Update - Buying Apple, AbbVie And BMW
It's November and the year is coming to an end, fast and furious. Global stock markets rallied in November and despite still being hampered by the strong euro my portfolio also appreciated quite significantly driven mostly by Altria ( MO ) and AT&T ( T ). The expected corporate tax refor...
Source: SeekingAlpha
Date: December, 15 2017 10:36
My Journey To Financial Independence: 83-Stock September Portfolio Update - Buying AT&T, Honeywell, And Microsoft
It is end of quarter and September was the second best month in terms of dividend income. I personally was injured pretty much throughout September suffering from infections and over-stressing in my hands which mostly prevented me from writing but still allowed me to closely track the markets....
Source: SeekingAlpha
Date: October, 09 2017 18:05

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-07N/A11.00N/AN/A0
2018-12-06N/A11.00N/AN/A0
2018-12-05N/A11.00N/AN/A0
2018-12-04N/A11.00N/AN/A0
2018-12-03N/A11.00N/AN/A0

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-11-30100100100.0000Short
2018-11-15200200100.0000Short
2018-10-31200200100.0000Short
2018-10-12200200100.0000Short
2018-08-28200200100.0000Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on MDGEF.


About MediGene AG (OTC: MDGEF)

Logo for MediGene AG (OTC: MDGEF)

Medigene is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. Medigene concentrates on the development of personalized T cell immunotherapies with a focus on haematological malignancies. Medigene is the first German biotech company to have revenues from a marketed product, which is distributed by commercial partner companies. Medigene has advanced drug candidates which are licensed to partners and additional candidates in clinical development. The company is developing highly innovative treatment platforms concentrating on cancer and autoimmune diseases.

 

Contact Information

 

 

Current Management

  • Peter Heinrich / CEO
  • Peter Llewellyn Davies / CFO

Current Share Structure

     



    Daily Technical Chart for (OTC: MDGEF)

    Daily Technical Chart for (OTC: MDGEF)


    Stay tuned for daily updates and more on (OTC: MDGEF)

    It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

    More to come on (OTC: MDGEF)

    Do your DD and if you choose, be ready to go!


     

    The Research: All source information contained in this email is from the public sources mentioned below.

     

     
     

    Thank you

    DD Report
    @DDReports

     

     


    Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in MDGEF is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of MDGEF and does not buy, sell, or trade any shares of MDGEF. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/